Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
Aclarion (NASDAQ: ACON) has announced expansion plans for its Nociscan technology across multiple sites in New York and New Jersey through RadNet affiliates. Lenox Hill Radiology (LHR), operating 79 locations in New York, and New Jersey Imaging Network (NJIN), with 33 locations, will increase Nociscan accessibility in response to growing market demand.
The expansion builds on existing Nociscan sites and is facilitated by increased MR Spectroscopy (MRS) availability and enhanced remote operations capabilities within RadNet. LHR Park Avenue serves leading spine physicians from private practices and organizations like Weill Cornell, while NJIN-Union supports both local and out-of-market referrals through convenient airport access.
Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively identify painful discs in the lumbar spine, demonstrating a 97% surgical success rate when all pain-positive discs identified by Nociscan are treated.
Aclarion (NASDAQ: ACON) ha annunciato piani di espansione per la sua tecnologia Nociscan in diversi siti di New York e New Jersey attraverso le affiliate RadNet. Lenox Hill Radiology (LHR), che gestisce 79 sedi a New York, e New Jersey Imaging Network (NJIN), con 33 sedi, aumenteranno l'accessibilità di Nociscan in risposta alla crescente domanda di mercato.
L'espansione si basa sui siti Nociscan esistenti ed è facilitata dal miglioramento della disponibilità della spettroscopia MR (MRS) e delle capacità operative remote all'interno di RadNet. LHR Park Avenue serve medici specializzati nella colonna vertebrale provenienti da studi privati e organizzazioni come Weill Cornell, mentre NJIN-Union supporta sia i rinvii locali che quelli da fuori mercato grazie a un comodo accesso aeroportuale.
Nociscan è la prima piattaforma SaaS supportata da evidenze che aiuta i medici a identificare in modo non invasivo i dischi dolorosi nella colonna lombare, dimostrando un tasso di successo chirurgico del 97% quando tutti i dischi positivi al dolore identificati da Nociscan vengono trattati.
Aclarion (NASDAQ: ACON) ha anunciado planes de expansión para su tecnología Nociscan en múltiples sitios de Nueva York y Nueva Jersey a través de las afiliadas de RadNet. Lenox Hill Radiology (LHR), que opera 79 ubicaciones en Nueva York, y New Jersey Imaging Network (NJIN), con 33 ubicaciones, aumentarán la accesibilidad de Nociscan en respuesta a la creciente demanda del mercado.
La expansión se basa en los sitios existentes de Nociscan y se facilita mediante una mayor disponibilidad de espectroscopia por resonancia magnética (MRS) y capacidades mejoradas de operaciones remotas dentro de RadNet. LHR Park Avenue atiende a médicos líderes en columna vertebral de prácticas privadas y organizaciones como Weill Cornell, mientras que NJIN-Union apoya tanto referencias locales como de fuera del mercado a través de un conveniente acceso al aeropuerto.
Nociscan es la primera plataforma SaaS respaldada por evidencia que ayuda a los médicos a identificar de manera no invasiva discos dolorosos en la columna lumbar, demostrando una tasa de éxito quirúrgico del 97% cuando se tratan todos los discos positivos al dolor identificados por Nociscan.
Aclarion (NASDAQ: ACON)은 RadNet 제휴사를 통해 뉴욕과 뉴저지의 여러 사이트에 Nociscan 기술 확장 계획을 발표했습니다. 뉴욕에서 79개 지점을 운영하는 Lenox Hill Radiology (LHR)와 33개 지점을 가진 New Jersey Imaging Network (NJIN)은 증가하는 시장 수요에 대응하여 Nociscan 접근성을 높일 것입니다.
이 확장은 기존 Nociscan 사이트를 기반으로 하며, RadNet 내에서 증가된 MR 분광법(MRS) 가용성과 향상된 원격 운영 능력에 의해 촉진됩니다. LHR Park Avenue는 Weill Cornell과 같은 조직 및 개인 개업의로부터 최고의 척추 의사들에게 서비스를 제공하며, NJIN-Union은 편리한 공항 접근을 통해 지역 및 외부 시장의 의뢰를 지원합니다.
Nociscan은 의사들이 비침습적으로 요추의 아픈 디스크를 식별하는 데 도움을 주는 최초의 증거 기반 SaaS 플랫폼으로, Nociscan에 의해 식별된 모든 통증 양성 디스크가 치료될 때 97%의 수술 성공률을 보여줍니다.
Aclarion (NASDAQ: ACON) a annoncé des plans d'expansion pour sa technologie Nociscan sur plusieurs sites à New York et New Jersey via des affiliés de RadNet. Lenox Hill Radiology (LHR), qui exploite 79 emplacements à New York, et New Jersey Imaging Network (NJIN), avec 33 emplacements, vont accroître l'accessibilité de Nociscan en réponse à la demande croissante du marché.
L'expansion s'appuie sur les sites Nociscan existants et est facilitée par une disponibilité accrue de la spectroscopie par IRM (MRS) et des capacités d'opérations à distance améliorées au sein de RadNet. LHR Park Avenue sert des médecins spécialisés en colonne vertébrale provenant de pratiques privées et d'organisations telles que Weill Cornell, tandis que NJIN-Union soutient à la fois les références locales et celles venant de l'extérieur du marché grâce à un accès aéroportuaire pratique.
Nociscan est la première plateforme SaaS soutenue par des preuves qui aide les médecins à identifier de manière non invasive des disques douloureux dans la colonne lombaire, affichant un taux de réussite chirurgicale de 97 % lorsque tous les disques positifs à la douleur identifiés par Nociscan sont traités.
Aclarion (NASDAQ: ACON) hat Expansionspläne für seine Nociscan Technologie an mehreren Standorten in New York und New Jersey über RadNet-Partner angekündigt. Lenox Hill Radiology (LHR), die 79 Standorte in New York betreibt, und New Jersey Imaging Network (NJIN), mit 33 Standorten, werden die Zugänglichkeit von Nociscan als Reaktion auf die wachsende Marktnachfrage erhöhen.
Die Expansion baut auf bestehenden Nociscan-Standorten auf und wird durch die erhöhte Verfügbarkeit von MR-Spektroskopie (MRS) sowie verbesserte Remote-Operationsfähigkeiten innerhalb von RadNet erleichtert. LHR Park Avenue bedient führende Wirbelsäulenärzte aus Privatpraxen und Organisationen wie Weill Cornell, während NJIN-Union sowohl lokale als auch externe Überweisungen durch bequemen Flughafenzugang unterstützt.
Nociscan ist die erste evidenzgestützte SaaS-Plattform, die Ärzten hilft, schmerzhafte Bandscheiben in der Lendenwirbelsäule nicht-invasiv zu identifizieren, und zeigt eine chirurgische Erfolgsquote von 97%, wenn alle schmerzpositiven Bandscheiben, die von Nociscan identifiziert wurden, behandelt werden.
- Significant expansion across 112 potential locations in NY and NJ
- 97% surgical success rate with Nociscan-guided treatments
- Partnership with major imaging provider RadNet strengthened
- Access to high-value medical market through Weill Cornell association
- None.
Insights
Aclarion's expansion of its Nociscan technology across RadNet affiliates in New York and New Jersey represents a strategic growth initiative with potential long-term revenue implications. By increasing accessibility through Lenox Hill Radiology's 79 New York locations and New Jersey Imaging Network's 33 facilities, Aclarion is positioning its diagnostic platform to reach a significantly larger patient population in densely populated metropolitan areas.
The expansion appears market-driven, with the company citing increased physician demand as a key factor. This suggests growing clinical interest in Nociscan's capabilities, particularly its ability to objectively identify painful discs in patients with chronic low back pain—a condition affecting approximately
From an operational perspective, the announcement highlights two enabling factors: increased availability of MR Spectroscopy (MRS) technology across RadNet's network and enhanced remote operations capabilities. These technical developments are important for Aclarion's scaling strategy, as they allow for more efficient implementation and operation of the Nociscan platform without requiring substantial on-site resources at each location.
The expansion builds upon existing relationships rather than establishing new partnerships, indicating validation of the technology's clinical utility by current users. Notable is the mention of serving physicians from prestigious institutions like Weill Cornell, suggesting acceptance among influential medical professionals.
While the announcement lacks specific financial projections or implementation timelines, the strategic value is evident. Aclarion's relationship with RadNet—one of the nation's largest outpatient imaging providers—creates a substantial distribution channel for its technology. However, investors should note that imaging technology adoption typically follows a gradual curve, requiring physician education and established reimbursement pathways before significant scan volumes materialize.
The expansion represents positive momentum in Aclarion's commercialization strategy, though the timeline to meaningful revenue impact remains undefined based on the information provided.
Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites
BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet affiliates in both states and are driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan.
“Expanding scanner access is a key element of our strategy to drive Nociscan to standard of care for patients with chronic low back pain,” said Brent Ness, Chief Executive Officer of Aclarion. “The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this important national imaging provider.”
Lenox Hill Radiology (LHR) operates convenient, outpatient imaging centers located in the metropolitan New York area, and 79 total locations throughout New York state. LHR Park Avenue, a flagship site, initially adopted Nociscan to provide access to leading spine physicians in private practice and from globally recognized organizations such as Weill Cornell.
New Jersey Imaging Network (NJIN) is one of the largest imaging providers in NJ with 33 locations. NJIN-Union, in metro NJ, was the first site in NJ to adopt Nociscan to support both local physicians and out-of-market referrals through the convenience of Newark Liberty International Airport and Teterboro Airport.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contact:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
What is the success rate of surgeries using Aclarion's Nociscan technology?
How many locations will offer Nociscan through the RadNet expansion in NY and NJ?
What is unique about Aclarion's Nociscan technology for chronic back pain?
Which major medical institutions are already using Nociscan in New York?
